ADARx Pharmaceuticals Surges After Upsized IPO
ADRX is trading near its 52-week low of $19 (1.8% below the low).
Summary
ADARx Pharmaceuticals completed an upsized IPO, with shares surging in early trading. The company priced the offering above its initial range, reflecting strong investor demand for the RNA-editing biotech. The IPO priced 26.25M shares at $17.00, raising $446.25M before underwriting discounts; AbbVie will buy 5,233,264 shares in a concurrent private placement at the IPO price. The stock is trading near its 52-week low, so the IPO pop is a notable reversal. The upsizing suggests underwriters saw sufficient demand to increase the deal size, a positive signal for the company's capital position. Watch for post-IPO lockup expiration and any clinical updates that could drive further moves.
Updated with an SEC 424B4 filing · What changed
Updates
· SEC 424B4 — The IPO priced 26.25M shares at $17.00, raising $446.25M before underwriting discounts; AbbVie will buy 5,233,264 shares in a concurrent private placement at the IPO price.
At the time of this announcement, ADRX was trading at $18.65 on NASDAQ in the Life Sciences sector. The 52-week trading range was $19.00 to $23.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.